Immunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2

Background: In 2020, the pandemic caused by novel coronavirus infection has become one of most critical global health challenges during past century. The lack a vaccine, as effective way to control infection, prompted development large number preventive products scientific community. We have developed candidate vaccine (EpiVacCorona) against SARS-CoV-2 that is based on chemically synthesized peptides conjugated carrier protein and adsorbed aluminum hydroxide studied specific activity vaccine.
 Aims: Study immunogenicity protectivity peptide EpiVacCorona.
 Materials methods: work was performed using standard molecular biological, virological histological methods.
 Results: It demonstrated EpiVacCorona, when administered twice, spaced 14 days apart, hamsters, ferrets, non-human primates (African green monkeys, rhesus macaques) at dose 260 g, which equal inoculation for humans, induces virus-specific antibodies in 100% animals. Experiments hamsters showed this be associated with dose-dependent immunogenicity. shown accelerate elimination virus from upper respiratory tract ferrets prevent pneumonia following challenge coronavirus.
 Conclusions: results preclinical study indicate use EpiVacCorona potential human vaccination.